Physician profile
Robert Broker
NPI 1558304550
$2,415.42
in general payments reported to CMS, 2019-2025
30 companies · $547 in 2025
The $547 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $72.46 · 2021: $11.43 · 2022: $111 · 2023: $412 · 2024: $539 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $322.74 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Abbott Laboratories | $285.66 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Novo Nordisk INC | $239.52 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $228.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $217.93 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $168.44 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.60 | 2019-2025 | Synjardy, Jardiance, Tradjenta |
| Lilly USA, LLC | $122.73 | 2022-2025 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $115.19 | 2019-2024 | Otezla, Repatha |
| Astellas Pharma US INC | $81.56 | 2019-2024 | Veozah |
| Daiichi Sankyo INC. | $63.67 | 2022-2024 | Injectafer |
| Dexcom, INC. | $58.98 | 2024-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $56.70 | 2019 | |
| Novartis Pharmaceuticals Corporation | $53.68 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $39.20 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $38.74 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $33.79 | 2019-2020 | |
| Eisai INC. | $31.77 | 2025 | |
| Xeris Pharmaceuticals, INC. | $20.52 | 2024 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $16.63 | 2025 | Nexletol |
| Currax Pharmaceuticals LLC | $15.70 | 2025 | Contrave |
| Phathom Pharmaceuticals, INC. | $15.00 | 2024 | Voquezna |
| Genentech USA, INC. | $14.43 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.71 | 2022 | |
| Ironshore Pharmaceuticals INC. | $12.99 | 2019 | |
| Shire North American Group INC | $12.23 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.99 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Broker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.